Being tested
Efgartigimod alfa: reduce relapses and new lesions in relapsing MS
relapsing MS · FcRn / IgG reduction, IVIG, plasma exchange
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 1
- Running now
- 1
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 1
These linked trials do not set the status.
- Efgartigimod as a first line attack therapy in demyelinating diseases of the central nervous systemOngoing
Phase 2/3 · 2026 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28First listed as Being tested
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error